- US-listed companies
- Addex Therapeutics Ltd.
Addex Therapeutics Ltd.ADXN
Market cap
P/E ratio
Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
Revenue from contract with customer | - | 4 | 3 | 1 |
Other income | - | 266,324 | 236,997 | 22,521 |
Research and development | - | 10 | 13 | 15 |
General and administration | - | 6 | 6 | 7 |
Total operating costs | - | 16 | 19 | 22 |
Operating loss | - | -12,243,274 | -15,505,917 | -20,520,207 |
Finance income | - | 35,304 | 217,015 | 29,251 |
Finance expense | - | 650,629 | 63,012 | 313,257 |
Finance result, net | - | -615,325 | 154,003 | -0 |
Net loss before tax | - | -12,858,599 | -15,351,914 | -20,804,213 |
Income tax expense | - | - | - | - |
Net loss for the year | -14,780,604 | -12,858,599 | -15,351,914 | -20,804,213 |
Basic earnings (loss) per share | - | - | -0.45 | -0.46 |
Diluted earnings (loss) per share | - | - | -0.45 | -0.46 |
Remeasurements of retirement benefits obligation | -745,855 | -233,529 | 260,548 | 1 |
Exchange difference on translation of foreign operations | -838 | -4,069 | -295 | -345 |
Other comprehensive income/(loss) for the year, net of tax | -746,693 | -237,598 | 260,253 | 1 |
Total comprehensive loss for the year | -15,527,297 | -13,096,197 | -15,091,661 | -19,534,426 |